Mesoblast Director Eric Allen Files Decade‑Long Options Deal – Insider Confidence Amid Sluggish Stock Performance
Insider filing reveals Mesoblast’s leadership confidence—options tied to 2030‑2032 milestones may boost the stock if R&D Day succeeds, but risk a bearish outcome if targets miss.
4 minutes to read